Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma
Vijay Sagar Madamsetty(Jacksonville College), Hsu‐Shan Huang(Taipei Medical University), Debabrata Mukhopadhyay(Jacksonville College), Kabir Mody(Mayo Clinic in Florida), Thomas R. Caulfield(Jacksonville College), Enfeng Wang(Jacksonville College), Shamit K. Dutta(WinnMed), Krishnendu Pal(Jacksonville College), James Thompson(University of Mississippi Medical Center), Yun Yen(City Of Hope National Medical Center)
Cited by 19
Related Papers
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Enabling Technologies for Personalized and Precision Medicine
|Trends in biotechnology|2020|483
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
|Journal of Clinical Oncology|2022|398
In vivo gene delivery mediated by non-viral vectors for cancer therapy
|Journal of Controlled Release|2020|240